You are here

Wearable Autoinjector for Wound Infection Treatment

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: HT9425-23-C-0014
Agency Tracking Number: H2-0718
Amount: $1,099,368.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: DHA213-009
Solicitation Number: 21.3
Solicitation Year: 2021
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-03-01
Award End Date (Contract End Date): 2025-07-07
Small Business Information
330 Billerica Road Ste 200
CHELMSFORD, MA 01824-0440
United States
DUNS: 796010411
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Chris Hale
 (978) 240-4200
Business Contact
 Collette Jolliffe
Phone: (978) 856-4158
Research Institution

The proposed program addresses the need to replace the combat wound medication packet (CWMP) with a wearable device capable of delivering treatment for the prevention of infection in a prolonged care setting. The ability to treat penetrating wounds with antibiotics before surgery will be a major hurdle in maintaining combat power. In response to this need, Triton Systems, Inc. has leveraged its existing efforts in wearable devices and microfluidic platforms to develop a novel wearable autoinjector for continuous drug delivery in prolonged care scenarios. In the Phase I program, Triton designed and developed proof-of-concept prototypes demonstrating the capability to meet treatment delivery requirements. In the proposed Phase II program, Triton will further refine the Phase I proof-of-concept prototype, maturing it into a viable product. This will include an optimization of our wearable autoinjector for demonstration of deep treatment penetration and prevention of infection.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government